Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Dec 23, 2015 at 7:45 AM EST

Why Breakthrough FDA Approval of Gout Treatment May Matter So Much

Good news for those who suffer from high levels of uric acid and from gout: the FDA has approved a…

Chris Lange | Dec 22, 2015 at 11:45 AM EST

pSivida Soars on Positive Late Stage Results

pSivida was leading the bulls in Tuesday’s session on positive results from a late stage trial of Medidur.

Chris Lange | Dec 21, 2015 at 11:35 AM EST

How AVEO Is Winning on Its Newest Licensing Agreement

AVEO Pharmaceuticals was leading the bulls in Monday’s session on news of an exclusive licensing agreement.

Chris Lange | Dec 21, 2015 at 11:05 AM EST

Collegium Pharma Announces Secondary Offering

Collegium Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.

Chris Lange | Dec 21, 2015 at 9:10 AM EST

KemPharm Prepares for Secondary Offering

KemPharm expects to price its 3 million shares around last Thursday's closing price of $18.88, which would value the entire…

Chris Lange | Dec 18, 2015 at 9:45 AM EST

Intercept Pharma Disappoints on FDA Extension

Intercept Pharmaceuticals announced that the FDA has extended the PDUFA date for its Priority Review of obeticholic acid in primary…

Trey Thoelcke | Dec 18, 2015 at 7:10 AM EST

4 Top Biotech Stocks for 2016

Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better…

Chris Lange | Dec 17, 2015 at 10:20 AM EST

Martin Shkreli Stocks Turn Toxic Upon Arrest

As quickly as KaloBios Pharmaceuticals shares shot up, they are dropping after its newly named chief executive, Martin Shkreli, was…

Lee Jackson | Dec 17, 2015 at 8:20 AM EST

Top Cowen Health Care and Biotech Best Idea Stock Picks for 2016

All these Cowen picks offer compelling values for 2016, and all have backed up enough in price for investors to…

Chris Lange | Dec 16, 2015 at 10:10 AM EST

Advaxis Skyrockets on Resumed Clinical Trials

Advaxis has announced that the FDA has lifted the clinical hold on all of its Investigational New Drug (IND) applications…

Chris Lange | Dec 16, 2015 at 8:45 AM EST

Array BioPharma Rallies on Late-Stage Win

Array BioPharma reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma,…

Jon C. Ogg | Dec 15, 2015 at 4:52 PM EST

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a…

Chris Lange | Dec 15, 2015 at 4:29 PM EST

Lakeland Stumbles on Mixed Earnings

Lakeland Industries reported mixed fiscal 2016 third-quarter financial results after the markets closed on Tuesday.

Chris Lange | Dec 15, 2015 at 1:20 PM EST

Pacira Pharma Soars on Settled FDA Case

Pacira Pharmaceuticals announced that it achieved an amicable resolution with the FDA for a lawsuit filed earlier this year that…

Chris Lange | Dec 15, 2015 at 1:15 PM EST

Why Neothetics Is Getting Destroyed

Neothetics Inc. (NASDAQ: NEOT) was absolutely crashed in Tuesday’s session after announcing top-line results from a late stage trial that…

1 … 230 231 232 233 234 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Breakthrough FDA Approval of Gout Treatment May Matter So Much

pSivida Soars on Positive Late Stage Results

How AVEO Is Winning on Its Newest Licensing Agreement

Collegium Pharma Announces Secondary Offering

KemPharm Prepares for Secondary Offering

Intercept Pharma Disappoints on FDA Extension

4 Top Biotech Stocks for 2016

Martin Shkreli Stocks Turn Toxic Upon Arrest

Top Cowen Health Care and Biotech Best Idea Stock Picks for 2016

Advaxis Skyrockets on Resumed Clinical Trials

Array BioPharma Rallies on Late-Stage Win

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Lakeland Stumbles on Mixed Earnings

Pacira Pharma Soars on Settled FDA Case

Why Neothetics Is Getting Destroyed

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Health and Healthcare Articles

All Health and Healthcare Articles

Why Breakthrough FDA Approval of Gout Treatment May Matter So Much

pSivida Soars on Positive Late Stage Results

How AVEO Is Winning on Its Newest Licensing Agreement

Collegium Pharma Announces Secondary Offering

KemPharm Prepares for Secondary Offering

Intercept Pharma Disappoints on FDA Extension

4 Top Biotech Stocks for 2016

Martin Shkreli Stocks Turn Toxic Upon Arrest

Top Cowen Health Care and Biotech Best Idea Stock Picks for 2016

Advaxis Skyrockets on Resumed Clinical Trials

Array BioPharma Rallies on Late-Stage Win

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Lakeland Stumbles on Mixed Earnings

Pacira Pharma Soars on Settled FDA Case

Why Neothetics Is Getting Destroyed

Live: Will Oracle Crush Q4 Earnings After the Market Closes Tonight?

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation